Table 1:
Demographic characteristics, liver/hepatitis B virus test results, fibrosis and antiviral therapy of Canadians with chronic hepatitis B, by province
| Variable | Province; no. (%) of patients* (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total n = 9380 |
BC n = 1535 |
Alta. n = 1814 |
Sask. n = 179 |
Man. n = 1051 |
Ont. n = 4637 |
Que. n = 132 |
NS n = 19 |
NL n = 13 |
|
| Age, yr, mean (median) | 49.1 (48) (48.80–49.36) | 52.7‡ (53) (52.01–53.35) | 45.6‡ (44) (45.01–46.21) | 44.3 (41) (42.22–46.42) | 46.6‡ (46) (45.76–47.37) | 50.0‡ (50) (49.62–50.44) | 49.6 (47) (47.28–51.84) | 40.9‡ (36) (34.47–47.32) | 44.5 (50) (37.73–51.20) |
| Male sex | 5193 (55.4) (54.35–56.37) | 864 (56.3) (53.76–58.78) | 919 (50.7)‡ (48.33–52.99) | 106 (59.2) (51.62–66.42) | 558 (53.1) (50.02–56.14) | 2642 (57.0)‡ (55.54–58.41) | 81 (61.4) (52.47–69.59) | 13 (68.4) (43.50–86.44) | 10 (76.9) (45.98–93.84) |
| Born in Canada | 80 (0.8) (0.68–1.07) | 5 (0.3)‡ (0.12–0.81) | 4 (0.2)‡ (0.07–0.60) | 3 (1.7)‡ (0.43–5.21) | 0 (0.0)‡ | 68 (1.5)‡ (1.15–1.87) | 0 (0.0)‡ | 0 (0.0)‡ | 0 (0.0) |
| Immigrant status missing | 7063 (75.3) (74.41–76.17) | 939 (61.2)‡ (58.68–63.61) | 1398 (77.1)‡ (75.05–78.97) | 84 (46.9)‡ (39.49–54.50) | 693 (65.9)‡ (62.97–68.79) | 3797 (81.9)‡ (80.74–82.98) | 132 (100.0)‡ (96.48–100.00) | 7 (36.8)‡ (17.23–61.37) | 13 (100.0) (71.66–100.00) |
| Asian | 5803 (61.9) (60.87–62.85) | 1120 (73.0)‡ (70.65–75.16) | 1109 (61.1)‡ (58.84–63.38) | 97 (54.2)‡ (46.60–61.59) | 252 (24.0)‡ (21.45–26.70) | 3198 (69.0)‡ (67.61–70.29) | 13 (9.8)‡ (5.56–16.57) | 11 (57.9) (33.97–78.88) | 3 (23.1)‡ (6.16–54.02) |
| Black | 916 (9.8) (9.18–10.39) | 16 (1.0)‡ (0.62–1.73) | 272 (15.0)‡ (13.40–16.74) | 34 (19.0)‡ (13.68–25.67) | 76 (7.2)‡ (5.77–9.01) | 498 (10.7)‡ (9.87–11.67) | 17 (12.9)‡ (7.90–20.09) | 2 (10.5) (1.84–34.54) | 1 (7.7)‡ (0.40–37.91) |
| White | 914 (9.7) (9.16–10.37) | 32 (2.1)‡ (1.45–2.97) | 94 (5.2)‡ (4.23–6.33) | 24 (13.4)‡ (8.95–19.49) | 21 (2.0)‡ (1.27–3.09) | 664 (14.3)‡ (13.33–15.37) | 79 (59.8)‡ (50.94–68.17) | 0 (0.0) | 0 (0.0)‡ |
| Ethnicity missing | 1522 (16.2) (15.49–16.99) | 343 (22.3)‡ (20.30–24.53) | 305 (16.8)‡ (15.14–18.63) | 16 (8.9)‡ (5.36–14.35) | 690 (65.6)‡ (62.68–68.51) | 144 (3.1)‡ (2.63–3.66) | 12 (9.1)‡ (5.00–15.67) | 4 (21.0) (6.97–46.10) | 8 (61.5)‡ (32.28–84.87) |
| HBeAg-positive | 1240 (13.2) (12.54–13.93) | 232 (15.1)‡ (13.38–17.03) | 217 (12.0)‡ (10.52–13.57) | 30 (16.8)‡ (11.76–23.23) | 27 (2.6)‡ (1.73–3.77) | 697 (15.0)‡ (14.02–16.10) | 30 (22.7)‡ (16.08–31.00) | 3 (15.8) (4.17–40.49) | 4 (30.8) (10.36–61.12) |
| HBeAg status missing | 2584 (27.5) (26.65–28.47) | 713 (46.4)‡ (43.93–48.98) | 680 (37.5)‡ (35.26–39.77) | 14 (7.8)‡ (4.50–13.03) | 745 (70.9)‡ (68.02–73.60) | 421 (9.1)‡ (8.28–9.95) | 2 (1.5)‡ (0.26–5.92) | 4 (21.0) (6.97–46.10) | 5 (38.5) (15.13–67.72) |
| HBV DNA level < 2000 IU/mL | 2319 (24.7) (23.85–25.61) | 881 (57.4)‡ (54.87–59.88) | 582 (32.1)‡ (29.95–34.3) | 87 (48.6)‡ (41.12–56.15) | 480 (45.7)‡ (42.63–48.74) | 252 (5.4)‡ (4.81–6.14) | 27 (20.4)‡ (14.13–28.54) | 10 (52.6)‡ (29.50–74.79) | 0 (0.0) |
| HBV DNA level missing | 6560 (69.9) (68.99–70.86) | 654 (42.6)‡ (40.12–45.13) | 731 (40.3)‡ (38.04–42.60) | 92 (51.4)‡ (43.85–58.88) | 571 (54.3)‡ (51.26–57.37) | 4385 (94.6)‡ (93.86–95.19) | 105 (79.5)‡ (71.46–85.87) | 9 (47.4)‡ (25.21–70.50) | 13 (100.0) (71.66–100.00) |
| Alanine transaminase level, U/L, mean (median)† | 40.1 (27) (37.43–42.86) | 33.4 (25)‡ (30.67–36.10) | 38.0 (28) (33.11–42.81) | 36.9 (27) (27.00–46.89) | 51.3‡ (27) (42.32–60.32) | 39.2 (30) (36.34–41.98) | 43.8 (28) (33.43–54.10) | 30.1‡ (26) (23.66–36.58) | NA |
| Stage F3–4 fibrosis | 324 (3.4) (3.10–3.85) | 103 (6.7)‡ (5.53–8.11) | 113 (6.2)‡ (5.18–7.47) | 7 (3.9) (1.72–8.21) | 4 (0.4)‡ (0.12–1.04) | 96 (2.1)‡ (1.69–2.53) | 1 (0.8)‡ (0.04–4.77) | 0 (0.0)‡ | 0 (0.0)‡ |
| Fibrosis data missing | 5120 (54.6) (53.57–55.60) | 102 (6.6)‡ (5.47–8.04) | 962 (53.0)‡ (50.70–55.35) | 93 (52.0) (44.40–59.43) | 1004 (95.5)‡ (94.05–96.66) | 2807 (60.5)‡ (59.11–61.94) | 120 (90.9)‡ (84.33–95.00) | 19 (100.0)‡ (79.08–100.00) | 13 (100.0)‡ (71.66–100.00) |
| Lamivudine prescription (at any time) | 1434 (15.3) (14.57–16.04) | 386 (25.1)‡ (23.01–27.41) | 71 (3.9)‡ (3.09–4.94) | 1 (0.6)‡ (0.03–3.55) | 14 (1.3)‡ (0.76–2.28) | 958 (20.6)‡ (19.51–21.86) | 2 (1.5)‡ (0.26–5.92) | 1 (5.3)‡ (0.28–28.11) | 1 (7.7) (0.40–37.91) |
| Tenofovir disoproxil prescription (at any time) | 1655 (17.6) (16.88–18.43) | 376 (24.5)‡ (22.38–26.74) | 408 (22.5)‡ (20.60–24.50) | 17 (9.5)‡ (5.80–15.01) | 35 (3.3)‡ (2.36–4.65) | 788 (17.0) (15.93–18.11) | 30 (22.7) (16.08–31.00) | 1 (5.3)‡ (0.28–28.11) | 0 (0.0) |
| Entecavir prescription (at any time) | 548 (5.8) (5.38–6.34) | 80 (5.2)‡ (4.18–6.48) | 199 (11.0)‡ (9.59–12.52) | 0 (0.0)‡ | 9 (0.8) (0.42–1.68) | 259 (5.6) (4.95–6.30) | 1 (0.8)‡ (0.04–4.77) | 0 (0.0)‡ | 0 (0.0) |
| Treatment data missing | 139 (1.5) (1.25–1.75) | 0 (0.0)‡ | 0 (0.0)‡ | 66 (36.9)‡ (29.89–44.43) | 0 (0.0)‡ | 70 (1.5) (1.19–1.91) | 0 (0.0)‡ | 3 (15.8)‡ (4.17–40.49) | 0 (0.0) |
Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus, NA = not available.
*
Except where noted otherwise.
†
Data missing for 5487 patients overall: 112 from British Columbia, 1378 from Alberta, 74 from Saskatchewan, 32 from Manitoba, 3875 from Ontario, 14 from Quebec and 2 from Nova Scotia.
‡
p < 0.05 for difference between the value for a given province, and the national total minus the value for that province.